^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RGV004

    i
    Other names: RGV004
    Associations

    News

    Trials
    Company:
    Hangzhou Rongu Biotech
    Drug class:
    CD3 agonist, CD19 inhibitor, Cell death stimulant
    Related drugs:
    Associations

    News

    Trials
    over1year
    Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma (clinicaltrials.gov)
    P1, N=25, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open • Oncolytic virus
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    RGV004